Rocket Pharmaceuticals: Martin plans $128K share sale
The notice says the sale includes an amount needed to cover a tax obligation from settlement of the vested equity award distribution.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Rocket Pharmaceuticals, Inc. (RCKT) officer Wilson Martin reported a planned sale of 53,389 common shares through Fidelity Brokerage Services LLC on November 5, 2026, with an aggregate market value of $127,807.93. The shares are listed as arising from restricted stock vesting on November 4, 2026. The sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Vesting financial
vested equity award distribution financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What earlier RCKT stock sales are listed?
AI-generated analysis. How Rhea-AI works. Not financial advice.